Reference : Inefficacy of autologous bone marrow concentrate in stage three osteonecrosis: a rand...
Scientific journals : Article
Human health sciences : Rheumatology
http://hdl.handle.net/2268/214962
Inefficacy of autologous bone marrow concentrate in stage three osteonecrosis: a randomized controlled double-blind trial
English
HAUZEUR, Jean-Philippe mailto [Centre Hospitalier Universitaire de Liège - CHU > > Service de rhumatologie >]
De Maertelaer, Viviane  [Université Libre de Bruxelles - ULB > > > >]
BAUDOUX, Etienne mailto [Centre Hospitalier Universitaire de Liège - CHU > > Thérapie cellulaire >]
MALAISE, Michel mailto [Centre Hospitalier Universitaire de Liège - CHU > > Service de rhumatologie >]
Beguin, Yves mailto [Université de Liège - ULiege > > GIGA-R : Hématologie >]
Gangji, Valérie [Université Libre de Bruxelles - ULB > Hôpital Erasme > Department of Rheumatology and Physical Medicine > >]
7-Oct-2017
International Orthopaedics
Springer Verlag
Yes (verified by ORBi)
International
0341-2695
1432-5195
Berlin
Germany
[en] Osteonecrosis ; Femoral head ; Bone marrow aspirate concentrate  ; Cell therapy  ; Mesenchymal stem cells ; Hip
[en] Purpose
The fracture stage of non-traumatic osteonecrosis (ON stage 3) of the femoral head (ONFH) has an unfavourable prognosis frequently requiring total hip replacement (THR). The percentage could be lowered after core decompression. In earlier non-fracture ON stages, implantation of autologous bone marrow aspirate concentrate (BMAC) improved the effect of core decompression. The purpose was to evaluate the effect of BMAC in addition to core decompression in stage 3 ONFH.
Methods
A double blind RCT was conducted comparing two groups: core decompression plus saline injection or core decompression plus BMAC implantation. Both patients and assessors were blinded to the treatment assignments. Evaluations were done at baseline, three, six, 12, and 24 months, including pain (VAS), WOMAC, side-effects, radiological evolution including ARCO subclassifications, together with possible THR requirement. The primary endpoint was the need for THR. The second endpoints included the clinical symptoms such as pain and functional ability and the progression of the ON lesions as well as the appearance of osteoarthritis features (ARCO stage 4). Both groups included 23 hips (19 patients).
Results
No differences were found between the groups for THR requirements, clinical tests, and radiological evolution. In both groups, 15/23 hips needed THR. The radiological evolution of the ONFH lesions in term of location, extension, surface collapse, and dome depression was moderate in both groups and was not correlated with the need of THR.
Conclusions
Implantation of BMAC after core decompression did not produce any improvement of the evolution of ONFH stage 3.
Researchers ; Professionals
http://hdl.handle.net/2268/214962
10.1007/s00264-017-3650-8

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
Hauzeur-Inefficacy of autologous bone marrow concentrate in stage three osteonecrosis- a randomized controlled double-blind trial.pdfAuthor preprint447.81 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.